Effect of N-acetylglucosamine administration on cartilage metabolism and safety in healthy subjects without symptoms of arthritis: A case report

Kubomura,Daiki; Ueno,Tomoya; Yamada,Masanori; Tomonaga,Akihito; Nagaoka,Isao

doi:10.3892/etm.2017.4140

Effect of N-acetylglucosamine administration on cartilage metabolism and safety in healthy subjects without symptoms of arthritis: A case report

Authors:
- Daiki Kubomura
- Tomoya Ueno
- Masanori Yamada
- Akihito Tomonaga
- Isao Nagaoka
View Affiliations

Affiliations: Yaizu Suisankagaku Industry Co., Ltd., Yaizu, Shizuoka 425‑8570, Japan, Tana Orthopedic Surgery, Yokohama, Kanagawa 223‑0059, Japan, Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113‑8421, Japan
Published online on: February 21, 2017 https://doi.org/10.3892/etm.2017.4140
Pages: 1614-1621

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

N-acetylglucosamine (GlcNAc) is a widely accepted treatment for osteoarthritis (OA); however, its effect on healthy individuals is poorly understood. To evaluate the effect of GlcNAc administration on healthy subjects that do not exhibit symptoms of arthritis, the present randomized, double‑blind, placebo‑controlled study was performed. In the present study, 68 male and female Japanese participants, without symptomatic and radiographic evidence of OA, were enrolled and randomly allocated to receive placebo or GlcNAc (500 or 1,000 mg/day) for 16 weeks. Effects were evaluated using biomarkers for type II collagen degradation and synthesis, collagen type II cleavage (C2C), procollagen type II carboxy-terminal propeptide (PIICP) and their ratio (C2C/PIICP). Furthermore, safety assessments were performed via physical parameters, hematology, blood biochemistry and urinalysis. The results indicated that there was no significant change in the biomarkers for type II collagen degeneration and synthesis during and after the intervention with the placebo and two GlcNAc groups. However, subgroup analysis using subjects with impaired cartilage metabolism (who exhibited enhanced type II collagen degradation and reduced type II collagen synthesis) indicated that the C2C levels were significantly decreased at 8 (P<0.05) and 16 (P<0.01) weeks during the intervention in the two GlcNAc (500 mg and 1,000 mg/day) groups, compared with the placebo group. In contrast, PIICP levels were not notably different in the placebo and two GlcNAc groups. The C2C/PIICP ratio was markedly decreased at 12 and 16 weeks during the intervention in the two GlcNAc groups, compared with the placebo group. Moreover, no supplement‑related adverse events were observed during and after the intervention. In conclusion, these observations indicate that oral administration of GlcNAc at doses of 500 and 1,000 mg/day improves cartilage metabolism in healthy subjects without apparent adverse effects.

View Figures

View References

1	Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N and Reginster JY: Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res. 19:55–60. 2007. View Article : Google Scholar : PubMed/NCBI
2	Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, et al: Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: The research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 27:620–628. 2009. View Article : Google Scholar : PubMed/NCBI
3	Nakasone Y, Watabe K, Watanabe K, Tomonaga A, Nagaoka I, Yamamoto T and Yamaguchi H: Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study. Exp Ther Med. 2:893–899. 2011.PubMed/NCBI
4	Wieland HA, Michaelis M, Kirschbaum BJ and Rudolphi KA: Osteoarthritis-an untreatable disease? Nat Rev Drug Discov. 4:331–344. 2005. View Article : Google Scholar : PubMed/NCBI
5	Rashad S, Revell P, Hemingway A, Low F, Rainsford K and Walker F: Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 2:11491989. View Article : Google Scholar : PubMed/NCBI
6	Adams ME, Lussier AJ and Peyron JG: A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf. 23:115–130. 2000. View Article : Google Scholar : PubMed/NCBI
7	Anderson JW, Nicolosi RJ and Borzelleca JF: Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 43:187–201. 2005. View Article : Google Scholar : PubMed/NCBI
8	Chen JK, Shen CR and Liu CL: N-acetylglucosamine: Production and applications. Mar Drugs. 8:2493–2516. 2010. View Article : Google Scholar : PubMed/NCBI
9	Igarashi M, Kaga I, Takamori Y, Sakamoto K, Miyazawa K and Nagaoka I: Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes. Int J Mol Med. 27:821–827. 2011.PubMed/NCBI
10	Longas MO, Russell CS and He XY: Evidence for structural changes in dermatan sulfate and hyaluronic acid with aging. Carbohydr Res. 159:127–136. 1987. View Article : Google Scholar : PubMed/NCBI
11	Shuster S, Black MM and McVitie E: The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 93:639–643. 1975. View Article : Google Scholar : PubMed/NCBI
12	Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar : PubMed/NCBI
13	Herrero-Beaumont G, Ivorra JA, Del Carmen, Trabado M, Blanco FJ, Benito P, Martín-Mola E, Paulino J, Marenco JL, Porto A, Laffon A, et al: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 56:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S and Trelle S: Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-analysis. BMJ. 341:c46752010. View Article : Google Scholar : PubMed/NCBI
15	Hatano K, Hayashida K, Nakagawa S and Miyakuni Y: Effects and safety of soymilk beverage containing N-acetyl glucosamine on osteoarthritis. Jpn Pharmacol Ther. 34:149–165. 2006.
16	Qi C and Changlin H: Effects of moving training on histology and biomarkers levels of articular cartilage. J Surg Res. 135:352–363. 2006. View Article : Google Scholar : PubMed/NCBI
17	King KB, Lindsey CT, Dunn TC, Ries MD, Steinbach LS and Majumdar S: A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magn Reson Imaging. 22:1117–1123. 2004. View Article : Google Scholar : PubMed/NCBI
18	Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, et al: Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 60:1372–1380. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kellgren JH and Lawrence JS: Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 16:494–502. 1957. View Article : Google Scholar : PubMed/NCBI
20	Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat. 6:65–70. 1979.
21	Kajimoto O, Matahira Y, Kikuchi K, Sakamoto A, Kajiya Y and Hirata H: Effects of milk containing N-acetylglucosamine on osteoarthritis. J New Remedies Clin. 49:301–312. 2000.
22	Katsuno S, Sato K, Eguchi C, Yoshimura K, Yamamoto T, Tomonaga A and Nagaoka I: Effects and safety of milk beverage containing N-acetyl glucosamine on knee joint pain and biomarkers of type II collagen metabolism. Jpn Pharmacol Ther. 38:435–445. 2010.
23	Yokoi K and Fujimoto Y: Effect of dietary supplement containing N-acetylglucosamine on osteoarthritic pain and collagen biomarkers. J New Remedies Clin. 62:1758–1768. 2013.
24	Shoji A, Iga T, Inagaki S, Kobayashi K, Matahira Y and Sakai K: Metabolic disposition of [14C]N-acetyglucosamine in rats. Chitin Chitosan Res. 5:34–42. 1999.
25	Tamai Y, Miyatake K, Okamoto Y, Takamori Y, Sakamoto K and Minami S: Enhanced healing of cartilaginous injuries by N-acetyl-d-glucosamine and glucuronic acid. Carbohydr Polym. 54:251–262. 2003. View Article : Google Scholar
26	Shikhman AR, Brinson DC, Valbracht J and Lotz MK: Differential metabolic effects of glucosamine and N-acetylglucosamine in human articular chondrocytes. Osteoarthritis Cartilage. 17:1022–1028. 2009. View Article : Google Scholar : PubMed/NCBI
27	Julovi SM, Ito H, Nishitani K, Jackson CJ and Nakamura T: Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J Orthop Res. 29:258–264. 2011. View Article : Google Scholar : PubMed/NCBI
28	Yatabe T, Mochizuki S, Takizawa M, Chijiiwa M, Okada A, Kimura T, Fujita Y, Matsumoto H, Toyama Y and Okada Y: Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis. 68:1051–1058. 2009. View Article : Google Scholar : PubMed/NCBI
29	Shikhman AR, Kuhn K, Alaaeddine N and Lotz M: N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol. 166:5155–5160. 2001. View Article : Google Scholar : PubMed/NCBI
30	Takahashi M, Inoue K, Yoshida M, Morikawa T, Shibutani M and Nishikawa A: Lack of chronic toxicity or carcinogenicity of dietary N-acetylglucosamine in F344 rats. Food Chem Toxicol. 47:462–471. 2009. View Article : Google Scholar : PubMed/NCBI
31	Miwa I, Mita Y, Murata T, Okuda J, Sugiura M, Hamada Y and Chiba T: Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Enzyme Protein. 48:135–142. 1994.PubMed/NCBI
32	Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P and Thakkinstian A: Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: A systematic review and network meta-analysis. Eur J Med Res. 20:242015. View Article : Google Scholar : PubMed/NCBI